Research
Hormonal
Semaglutide 2.4 mg/week leads to significant weight loss and improvement in cardiovascular risk factors (blood pressure, lipids, inflammation) in overweight or obese adults without diabetes.
Semaglutide 2.4 mg/week helps overweight or obese individuals lose an average of 9.4% of their body weight over 104 weeks, compared to less than 1% with placebo. This weight loss is associated with improvements in blood pressure, cholesterol, and inflammation markers, contributing to better cardiovascular health.
StrongSupportsVERY_HIGH confidence
Mean change in body weight over 104 weeks was -9.4% and -0.9% with semaglutide and placebo, respectively; estimated treatment difference (ETT) -8.5% (95% CI, -8.5 to -8.3). There was significant amelioration in blood pressure and plasma levels of lipids, glycated hemoglobin (HbA1c), and C- reactive protein (CRP).
Why this rating
Based on the SELECT trial, a large, randomized, placebo-controlled trial.
Source
Semaglutide: The First Anti-Obesity Agent Shown to Decrease Cardiovascular Events
Nasser Mikhail et al. · Annals of Cardiovascular Diseases · 2024
narrative_review · n=17604Cited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →